<DOC>
	<DOCNO>NCT02431468</DOCNO>
	<brief_summary>This randomized double-blind placebo-controlled study compare different dos bryostatin treatment moderately severe severe Alzheimer 's disease . The study 15 week duration , include safety efficacy evaluation 30 day last dose study drug .</brief_summary>
	<brief_title>A Study Assessing Bryostatin Treatment Moderately Severe Severe Alzheimer 's Disease</brief_title>
	<detailed_description>This study enroll 150 moderately severe severe Alzheimer 's disease subject . Subjects randomly assign 1:1:1 treatment two different dos bryostatin 1 placebo . The primary analysis take place 12 week treatment ( 7 dos ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>Written inform consent caregiver subject ( possible ) legally acceptable representative different caregiver Male female subject 5585 year age inclusive Cognitive deficit present least 2 year meet diagnostic criterion probable Alzheimer 's Mini Mental State Exam ( MMSE2 ) score 415 Patients must able perform least one item Severe Impairment Battery Scale Neuroimaging ( computerize tomography ( CT ) Magnetic Resonance Imaging ( MRI ) ) within last 24 month consistent diagnosis probable Alzheimer 's disease ( AD ) Reliable caregiver ( ) informant ( ) attend subject least average 3 hour per day 3 day per week Adequate vision motor function comply test If take drug approve treatment Alzheimer 's disease ( e.g . cholinesterase inhibitor , memantine ) , must stable dose least 3 month prior entry study dose must change study unless change require due adverse event clinically significant change patient 's status . Dementia due condition AD , include vascular dementia ( Rosenmodified Hachinski lschemic score â‰¥ 5 ) Evidence significant central nervous system ( CNS ) vascular disease previous neuroimaging include limited : cortical stroke , multiple infarct , localize single infarct thalamus , angular gyrus , multiple lacunar infarct extensive white matter injury Clinically significant neurologic disease condition AD , cerebral tumor , chronic subdural fluid collection , Huntington 's Disease , Parkinson 's Disease , normal pressure hydrocephalus , diagnosis could interfere assessment safety efficacy Evidence clinically significant unstable cardiovascular , pulmonary , renal , hepatic , gastrointestinal , neurologic , metabolic disease within 6 month prior enrollment Poorly control diabetes , discretion Principal Investigator Creatinine clearance ( CL ) &lt; 45ml/min Use active Alzheimer 's vaccine within 2 year prior screen Use monoclonal antibody treatment AD within 1 year prior screen Any medical psychiatric condition likely require initiation additional medication surgical intervention course study Use investigational drug within 30 day prior screen Prior exposure bryostatin , know sensitivity bryostatin ingredient study drug Any concurrent medical condition , opinion PI make subject unsuitable clinical study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>